Feeds:
Posts
Comments

Posts Tagged ‘hiPSC’


Reporter and Curator: Dr. Sudipta Saha, Ph.D.

 

Parkinson’s Disease (PD), characterized by both motor and non-motor system pathology, is a common neurodegenerative disorder affecting about 1% of the population over age 60. Its prevalence presents an increasing social burden as the population ages. Since its introduction in the 1960’s, dopamine (DA)-replacement therapy (e.g., L-DOPA) has remained the gold standard treatment. While improving PD patients’ quality of life, the effects of treatment fade with disease progression and prolonged usage of these medications often (>80%) results in side effects including dyskinesias and motor fluctuations. Since the selective degeneration of A9 mDA neurons (mDANs) in the substantia nigra (SN) is a key pathological feature of the disease and is directly associated with the cardinal motor symptoms, dopaminergic cell transplantation has been proposed as a therapeutic strategy.

 

Researchers showed that mammalian fibroblasts can be converted into embryonic stem cell (ESC)-like induced pluripotent stem cells (iPSCs) by introducing four transcription factors i.e., Oct4, Sox2, Klf4, and c-Myc. This was then accomplished with human somatic cells, reprogramming them into human iPSCs (hiPSCs), offering the possibility of generating patient-specific stem cells. There are several major barriers to implementation of hiPSC-based cell therapy for PD. First, probably due to the limited understanding of the reprogramming process, wide variability exists between the differentiation potential of individual hiPSC lines. Second, the safety of hiPSC-based cell therapy has yet to be fully established. In particular, since any hiPSCs that remain undifferentiated or bear sub-clonal tumorigenic mutations have neoplastic potential, it is critical to eliminate completely such cells from a therapeutic product.

 

In the present study the researchers established human induced pluripotent stem cell (hiPSC)-based autologous cell therapy. Researchers reported a platform of core techniques for the production of mDA progenitors as a safe and effective therapeutic product. First, by combining metabolism-regulating microRNAs with reprogramming factors, a method was developed to more efficiently generate clinical grade iPSCs, as evidenced by genomic integrity and unbiased pluripotent potential. Second, a “spotting”-based in vitro differentiation methodology was established to generate functional and healthy mDA cells in a scalable manner. Third, a chemical method was developed that safely eliminates undifferentiated cells from the final product. Dopaminergic cells thus produced can express high levels of characteristic mDA markers, produce and secrete dopamine, and exhibit electrophysiological features typical of mDA cells. Transplantation of these cells into rodent models of PD robustly restored motor dysfunction and reinnervated host brain, while showing no evidence of tumor formation or redistribution of the implanted cells.

 

Together these results supported the promise of these techniques to provide clinically applicable personalized autologous cell therapy for PD. It was recognized by researchers that this methodology is likely to be more costly in dollars and manpower than techniques using off-the-shelf methods and allogenic cell lines. Nevertheless, the cost for autologous cell therapy may be expected to decrease steadily with technological refinement and automation. Given the significant advantages inherent in a cell source free of ethical concerns and with the potential to obviate the need for immunosuppression, with its attendant costs and dangers, it was proposed that this platform is suitable for the successful implementation of human personalized autologous cell therapy for PD.

 

References:

 

https://www.jci.org/articles/view/130767/pdf?elqTrackId=2fd7d0edee744f9cb6d70a686d7b273b

 

https://www.ncbi.nlm.nih.gov/pubmed/31714896

 

https://www.ncbi.nlm.nih.gov/pubmed/23666606

 

https://www.ncbi.nlm.nih.gov/pubmed/27343168

 

https://www.ncbi.nlm.nih.gov/pubmed/21495962

 

https://www.ncbi.nlm.nih.gov/pubmed/28083784

 

https://www.ncbi.nlm.nih.gov/pubmed/20336395

 

https://www.ncbi.nlm.nih.gov/pubmed/28585381

 

Read Full Post »


JNK/SAPK Signaling and iPSC

Larry H Bernstein, MD, FCAP, Curator

LPBI

 

JNK/SAPK Signaling is Essential for Efficient Reprogramming of Human Fibroblasts to Induced Pluripotent Stem Cells

Irina Neganova1, Evgenija Shmeleva1, Jennifer Munkley1, Valeria Chichagova1,…, David J. Elliott1, Lyle Armstrongand Majlinda Lako1,*

Stem Cells  4 MAR 2016    http://dx.doi.org:/10.1002/stem.2327

Reprogramming of somatic cells to the phenotypic state termed “induced pluripotency” is thought to occur through three consecutive stages: initiation, maturation, and stabilisation. The initiation phase is stochastic but nevertheless very important as it sets the gene expression pattern that permits completion of reprogramming; hence a better understanding of this phase and how this is regulated may provide the molecular cues for improving the reprogramming process. c-Jun N-terminal kinase (JNK)/stress-activated protein kinase (SAPKs) are stress activated MAPK kinases that play an essential role in several processes known to be important for successful completion of the initiation phase such as cellular proliferation, mesenchymal to epithelial transition (MET) and cell cycle regulation. In view of this, we postulated that manipulation of this pathway would have significant impacts on reprogramming of human fibroblasts to induced pluripotent stem cells. Accordingly, we found that key components of the JNK/SAPK signaling pathway increase expression as early as day 3 of the reprogramming process and continue to rise in reprogrammed cells throughout the initiation and maturation stages. Using both chemical inhibitors and RNA interference of MKK4, MKK7 and JNK1, we tested the role of JNK/SAPK signaling during the initiation stage of neonatal and adult fibroblast reprogramming. These resulted in complete abrogation of fully reprogrammed colonies and the emergence of partially reprogrammed colonies which disaggregated and were lost from culture during the maturation stage. Inhibition of JNK/SAPK signaling resulted in reduced cell proliferation, disruption of MET and loss of the pluripotent phenotype, which either singly or in combination prevented establishment of pluripotent colonies. Together these data provide new evidence for an indispensable role for JNK/SAPK signaling to overcome the well-established molecular barriers in human somatic cell induced reprogramming.

Our research group has a long standing interest in understanding the molecular mechanisms underpinning the induction of pluripotency which may be essential for enhancing the reprogramming process. In this manuscript, we have focused our attention on the c-Jun N-terminal kinase (JNK) signaling, a pathway which has been extensively studied in somatic and cancer cells, but it has been relatively unexplored in human pluripotent stem cells. Through a combination of techniques, we have been able to show that JNK/SAPK signaling is indispensable for overcoming several well described molecular barriers occurring in the initial stage of reprogramming, thus providing for the first time clear insights on the role of this pathway on human somatic cell induced reprogramming.

 

Since 2007, it has been possible to reprogram human somatic cells back to an embryonic stem cell (ESC) like stage via introduction of four transcription factors, namely OCT3/4, SOX2, KLF4, and c-MYC (referred as OSKM; [1]). The reprogrammed cells termed human induced pluripotent stem cells (hiPSCs), akin to human embryonic stem cells (hESCs) are characterized by the ability to proliferate indefinitely and have the potential to give rise to all cell types found in the adult organism [2]. The aforementioned pluripotency factors have also been implicated in the initiation of tumorigenesis in various tissues [3-5] and are considered as potent oncogenes. The risk associated with the introduction of these oncogenes in normal human somatic cells is the likely activation of anti-oncogenic pathways through a process named oncogenic stress which can often result in cell cycle arrest as a means of protection from tumorigenesis [6]. Activation of cell cycle arrest, p53 activation and reduced cellular proliferation have been described as molecular barriers to efficient reprogramming [7-9]. In view of these findings, we hypothesised that transduction of dermal skin (Fibroblasts: Lonza Group Ltd, Basel, Switzerland; Lonza:http://www.lonza.com/) with OSKM would activate oncogenic stress and induce growth arrest thus providing an additional barrier to reprogramming. Hence inhibition of key sensors of this pathway could provide useful targets for removing this barrier and increasing its efficiency.

Stress activated MAP kinase signaling pathways are important mediators of cellular responses to intra- and extracellular signals such as growth factors, hormones, and environmental stresses. These pathways consist of triple kinase cascades comprising the MAP kinases which are phosphorylated and activated by MAP kinase kinases (MKKs) and then further phosphorylated and activated by MAP kinase kinase kinases (MKKKs) [10]. In mammals, three distinct MAP kinase pathways have been identified resulting in activation of ERK, c-Jun N-terminal kinase (JNK) and p38 [10]. One of the key sensors of oncogenic stress is the JNK signaling pathway which responds by phosphorylating and stabilising p53 via its downstream mediator MKK7 [11]. The JNK pathway, also named stress-activated protein kinase pathway (SAPK) is essential for providing a cellular response to extracellular changes such as ultraviolet and reactive oxygen species induced damage, mechanical stress and osmolarity changes. For the JNK/SAPK pathway 14 different MKKs have been described to date [12]. MKK7 exclusively activates JNKs and MKK4 is unique in its ability to phosphorylate and activate two MAP kinase groups: JNKs and p38. Both MKK4 and MKK7 are responsible for phosphorylation of JNK/SAPKs at Tyrosine (Tyr) and Threonine (Thr) residues located at the activation loop. In murine embryonic stem cells (mESCs), MKK4 is shown to phosphorylate JNK/SAPKs at Tyr 185 residue, while MKK7 phosphorylates the Thr 183 residue, and together they cause dual phosphorylation of JNK/SAPKs, thus leading to its optimal activation [13].

Most of the data on JNK/SAPK signaling and activation of its targets has been obtained from work performed in somatic and cancer cells [14]; however in the last few years there have been a number of publications describing the role of this signaling pathway during embryonic development and in ESC function. Some of these have shown that MKK4 and MKK7 null mice die before E.12.5, highlighting the necessity of JNK/SAPK signaling pathway during embryonic development and suggesting that other pathways cannot substitute for MKK4 and MKK7 [15, 16]. Furthermore, JNK1 and JNK2 have been shown to play a negative role in the reprogramming of murine fibroblasts by suppressing Klf4 activity [17]. In contrast, hESCs are characterized by high levels of JNK/SAPK activity which is important for maintenance of pluripotency; however a role for this signaling pathway during reprogramming of human somatic cells has not been described previously and forms the main focus of this manuscript. We report herein that transduction of human fibroblasts with OSKM (both as single and polycistronic Sendai based viruses) induces the activation of JNK/SAPK signaling during the initiation and maturation stage of reprogramming. Downregulation of JNK/SAPK with a specific chemical inhibitor or by RNA interference (RNAi) leads to the emergence of only partially reprogrammed colonies which disaggregate and are lost during the maturation stage of reprogramming. Our data suggest that JNK/SAPK signaling plays an important role in several key processes that are shown to be important during cellular reprogramming namely the induction of mesenchymal to epithelial transition (MET), activation of cellular proliferation as well the maintenance of the pluripotent phenotype. Hence lack of hiPSC colonies and loss of partially reprogrammed cells can be attributed to one or more of these three cellular processes which are tightly regulated by JNK/SAPK signaling.

 

NK/SAPKs Kinases are Activated During the Course of Reprogramming

To understand the role of JNK/SAPKs during the generation of hiPSCs we assessed the expression of JNK1 and JNK2 and their upstream activators MKK4 and MKK7 in two different primary dermal skin fibroblasts (Neonatal/Neo1 and Adult/Ad3), several hiPSCs clones derived therefrom (Fig. 1A, 1B, Supporting Information Fig. 1B) and hESCs (H9). Human ESCs are characterised by high levels of JNK/SAPK activity which has been shown to be important for maintenance of the pluripotent stem cell state [19]. In accordance with this, we found the highest levels of mRNA JNK1 expression in hESCs when compared to several hiPSCs clones derived from two adult fibroblast samples (Fig. 1A, 1B, Supporting Information Fig. 1B); however these differences were not maintained at the protein level across the iPSC clones examined (Fig. 1B). We also observed that neonatal fibroblasts had lower expression of all four kinases examined when compared to adult fibroblasts (Fig. 1A, 1B). These differences were in part maintained in the respective hiPSC lines with the adult derived hiPSC clones showing higher expression of JNK1 when compared to neonatal derived hiPSCs at both transcript and protein level (Fig. 1A, 1B, Supporting Information Fig. 1A, 1B).

http://onlinelibrary.wiley.com/store/10.1002/stem.2327/asset/image_n/stem2327-fig-0001.png

Figure 1. JNK/SAPK signaling is activated during the initiation and maturation stage of reprogramming. (A): Real-time PCR analysis of MKK4, MKK7, JNK1and JNK2 expression in H9 (p36), neonatal human fibroblasts (Neo1), adult human fibroblasts (Ad3) and human induced pluripotent stem cell (hiPSC) generated therefrom (Neo1cl1iPSC and Ad3cl1iPSC, respectively). Data represent relative expression to GAPDH and normalized against H9. Data are presented as mean ± SEM. (B): Western blot analysis showing expression of MKK4, MKK7, JNK/SAPKs, pSAPK(Thr183/Tyr185) and pSAPK (Ser63) in hESC (H9), human neonatal fibroblasts (Neo1), human adult fibroblasts (Ad3) at Day 0 and hiPSC derived therefrom (Neo1cl1iPSC and Ad3cl1iPSC, respectively). (C): Western blot analysis of protein expression of MKK4, MKK7, JNK/SAPKs, pSAPK(Thr183/Tyr185) and pSAPK (Ser63) during the reprogramming of Neo1 fibroblasts. Days of transduction are indicated as D3—Day 3 and so on, correspondently. GAPDH served as loading control. Images are representative of at least three independent experiments. (D): Flow cytometric analysis of the distribution of TRA1-60+/CD44-, TRA1-60+/CD44 + and TRA1-60-/CD44 + populations during time course of reprogramming of neonatal (Neo1) and adult fibroblasts (Ad3). This is a representative example of at least three independent experiments. (E): Neo1 fibroblasts undergoing reprogramming were sorted in all four different subpopulation by FACS at day 13 of reprogramming and replated. The resulting colonies were stained by alkaline phosphatase at day 28. TRA1-60 + /CD44– cells formed numerous AP + colonies (upper panel), while TRA1-60+/CD44 + cells (lower panel) generated partly reprogrammed colonies. (F): Representative examples of flow cytometric analysis showing the distribution of pSAPK + cells among TRA1-60+/CD44-, TRA1-60+/CD44 + and TRA1-60-/CD44 + populations at day 10 of reprogramming of Neo1 fibroblasts. (G): Graphic representation of the percentage of p-SAPK + cells at different cells populations (TRA1-60+/CD44-, TRA1-60+/CD44 + and TRA1-60-/CD44+) during the reprogramming of Neo1 fibroblasts assessed by flow cytometric analysis. Data are presented as mean ± SEM. Abbreviations: FACS, Fluorescence-activated cell sorting; hESC, human embryonic stem cell; iPSC, induced pluripotent stem cell; JNK, c-Jun N-terminal kinase; MKK, MAP kinase kinases; SAPK, stress-activated protein kinase.

Transduction of OSKM caused a significant increase in JNK1 expression in adult fibroblasts and a dual increase in JNK1 and JNK2 expression in neonatal fibroblasts as early as day 3 of reprogramming (Fig. 1A-1C, Supporting Information Fig. 1A). This was followed by an increase in expression of pSAPK [Tyr 185/Thr 183SAPK)] from day 6 to day 21 in neonatal fibroblasts (Fig. 1B, 1C) and from day 12 to day 21 in adult fibroblasts (Fig. 1B, Supporting Information Fig. 1A). The expression of pSAPK (Ser63) was increased as early as day 3 continuing till day 21 of reprogramming in both neonatal and adult fibroblasts (Fig. 1B, 1C, Supporting Information Fig. 1A). Together these data suggest an increased JNK/SAPK activity during the initiation and maturation stage of reprogramming.

To determine how the four transcription factors (OSKM) individually contribute to JNK/SAPK activation during reprogramming, we performed transduction with each single factor in neonatal fibroblasts and substituted the rest of the factors with an equivalent number of control-GFP virus particles (Supporting Information Fig. 1C). Transduction withOCT4, KLF4 and c-MYC contributed mostly to an increase in JNK2 expression, while introduction of SOX2 increased both JNK1 and JNK2 expression with a preference for JNK1. Transduction with control viral particles alone did not lead to increased JNK1/JNK2 expression or their phosphorylated form (data not shown), indicating that activation of JNK/SAPK pathway during reprogramming is not related to the transduction event, but specifically to introduction of OSKM in somatic cells.

To further confirm the increase in p-JNK/SAPK expression at a cellular level, we used flow cytometric analysis as described previously [20]. This enabled us to follow three cellular subpopulations during the course of reprogramming; fully reprogrammed cells (TRA-1-60+CD44-), partially reprogrammed cells (TRA-1-60+CD44+) and fibroblasts (TRA-1-60-CD44+; Fig. 1D, 1E). pSAPK was expressed in all three subpopulations (Fig. 1F, 1G). It is interesting to note that the partially reprogrammed cells showed the highest percentage of pSAPK + expressing cells; however this declined toward the end of the reprogramming period (Fig. 1G). Furthermore, the percentage of pSAPK expressing cells increased in the fully reprogrammed subpopulation from day 14 to day 18 (Fig. 1G) then decreased by day 28, corroborating the Western blotting analysis (Fig. 1B, 1C, Supporting Information Fig. 1A). We obtained the same profile of emergence of the three cellular subpopulations and the same trend of pSAPK activation (Supporting Information Fig. 2A, 2B) upon application of a polycistronic Sendai vector (Cytotune 2.0), demonstrating that activation of JNK/SAPK is independent of hiPSC transduction protocol. Together these data suggest an important role for the activity of JNK/SAPK in fully reprogrammed cells during the maturation stage of reprogramming.

 

Inhibition of JNK/SAPK Activation with Chemical Inhibitors Causes Disaggregation and Loss of hiPSC Colonies During Maturation Stage

To test the function of JNK/SAPKs in generation of hiPSCs we used a small molecule SP600125, which has been shown to significantly inhibit expression of all three JNKgenes namely JNK1, JNK2, and JNK3 [21]. Our data show that 5 µM SP600125 (named SAPKi thereafter) is sufficient to downregulate the expression of JNK1 and JNK2 in hESCs (Fig. 2A) corroborating previous data published in mouse ESCs [22]. To investigate the impact of JNK/SAPK inhibition in the reprogramming process, we used SAPKi for 24 hours at different time points as summarized in Figure 2B and Supporting Information Figure 3. Our results indicate that application of SAPKi had a detrimental effect on hiPSC generation regardless of the time of application, for no hiPSC colonies were obtained at the end of the transduction period from either adult or neonatal fibroblasts (Fig.2F-2J, Supporting Information Fig. 3). In all cases, flow cytometric analysis indicated a significant decrease in the percentage of emerging hiPSCs (TRA-1-60+CD44-; Fig. 2B-2D). Furthermore, SAPKi application affected the TRA1-60 + populations specifically (partially reprogrammed and fully reprogrammed distinguished by presence or absence of CD44 respectively, Fig. 2C, 2D) as no reduction in the TRA-1-60-CD44 + population of dermal skin fibroblasts was observed (Fig. 2D). In control cultures (treated with DMSO vehicle only) we observed morphological changes (cells rounding up, starting to group together and showing morphology typical of pluripotent stem cells) which led to the emergence of hiPSC colonies with clear compact edges as early as day 16 (Fig. 2E, Supporting Information Fig. 3). In SAPKi treated cultures, we observed formation of colonies with morphology typical of partially reprogrammed cells; however most of these started to disintegrate as early as day 16 (Fig. 2E, 2D) and by day 18 all these partially reprogrammed colonies were lost from the culture (Fig. 2E).Thus, formation of hiPSCs colonies showing morphological features of pluripotent stem cells was not observed in the presence of SAPKi. Assessment of total colony number at the mid-point (day 16) as well as hiPSC colonies at day 28 (identified by alkaline phosphatase staining) corroborated the morphological and flow cytometric analysis and indicated no viable hiPSC colonies upon application of SAPKi (Fig. 2F, 2J), suggesting that JNK/SAPK activity is important for generation of hiPSCs colonies.

http://onlinelibrary.wiley.com/store/10.1002/stem.2327/asset/image_n/stem2327-fig-0002.png

Figure 2. Application of JNK/SAPKs inhibitor (SP60015) abrogates human induced pluripotent stem cell generation. (A): Western blot analysis of JNK/SAPKs downregulation by SP60015 (SAPKi) in hESCs (H9). GAPDH used as a loading control. Images are representative of at least three independent experiments. (B): Schematic representation of inhibitor application (SAPKi) at day 8 during the reprogramming process. (C): Graphic representation of flow cytometric analysis data (day 13) indicating a significant impact of SAPKi application (applied at day 8 for 24 hours) on the percentage of TRA1-60+/CD44- cells. Results are presented as mean ± SEM (n = 3). (D): Graphic representation of flow cytometric analysis data (day 13) demonstrating a significant impact of SAPKi application on TRA1-60+/CD44- and TRA1-60+/CD44 + subpopulations generated during reprogramming of Neo1 fibroblasts. Results are presented as mean ± SEM (n = 3). (E): Phase–contrast observation showing the morphology of partially reprogrammed colonies arising during the reprogramming of Neo1 and Ad3 fibroblasts treated with DMSO or SAPKi for 24 hours at day 8, scale bars = 100 µm. (F): Graphic representation of total colony numbers at day 16 and 28 of reprogramming in SAPKi and DMSO treated Neo1 and Ad3 fibroblasts. Data are presented as mean ± SEM (n = 3). (J): Alkaline phosphatase staining at day 28 confirmed the absence of true AP + colonies from neonatal and adult fibroblasts undergoing reprogramming and treated with SAPKi at day 8 of transduction for 24 hours. (C, D, F): *, p < .05. Abbreviations: AP, Alkaline phosphatase; DMSO, Dimethyl sulfoxide; FCM, Flow Cytometric and Morphological Analysis; JNK, c-Jun N-terminal kinase; SAPK, stress-activated protein kinase.

 

MKK4, MKK7 and JNK1/SAPK1 are Indispensable for hiPSC Generation

Impact of JNK/SAPK Downregulation on Pluripotent Stem Cells

Impact of JNK/SAPK Downregulation on Cellular Proliferation and Cell Cycle Regulation in Somatic Cells

Importance of JNK/SAPK Signaling for the MET

MET is an important process during somatic cell reprogramming and is orchestrated by the suppression of pro-epithelial to mesenchymal transition (EMT) signals and activation of an epithelial signature in reprogrammed cells [27]. During this process, two of the key reprogramming factors SOX2 and OCT4 suppress the EMT mediator SNAIL, while KLF4 induces epithelial gene expression including E-cadherin [27]. Ultrastructural visualization of this process has shown that until day 6 of reprogramming, human fibroblasts retain their mesenchymal characteristics. The MET occurs between days 6 and 12 and this is followed by maturation of the epithelial phenotype from day 12 to day 18 [28]. Although traditionally JNKs have been thought to be activated in response to apoptotic, proliferation and stress signals, more recently it has been shown that they can also act as cell junction regulators [29] and can be involved in cell migration which is tightly linked to dynamic formation as well as dissolution of cell-cell junctions[29, 30]. Given the importance of MET in hiPSC formation we asked whether inhibition of JNK/SAPK signaling leads to loss of E-cadherin expression-dependent adhesion, followed by loss of cell-to-cell communication resulting in disintegration of partially reprogrammed colonies and their loss from culture. Immunocytochemical analysis of OSKM treated control fibroblasts indicated formation of a bright network of E-cadherin and β-catenin plasma membrane staining in TRA-1-60 positive cells (Fig. 6A, 6B), indicating formation of adherent junctions between the cells. In contrast, E-cadherin and β-catenin staining was observed in very few of the cells present in the partially reprogrammed TRA-1-60 positive colonies obtained from reprogramming of JNK1 shRNA treated fibroblasts (Fig. 6A, 6B). Furthermore, the bright E-cadherin and β-catenin networks which ensure the cell-cell adhesion and communication were missing in reprogrammed JNK1 shRNA treated fibroblasts. Assessment of N-cadherin expression, a marker of fibroblasts that fail to undergo MET and further convert into hiPSC [31] indicated a higher number of expressing cells in JNK deficient cells (Fig. 6C), further supporting the disruption of MET during the reprogramming of JNK deficient samples. Quantitative RT-PCR analysis indicated downregulation of epithelial marker (E-cadherin) and upregulation of mesenchymal markers (SNAIL, N-cadherin, TWIST, VIMENTIN, ZEB1 and SLUG) under both Cytotune 1 and 2 Sendai reprogramming (Fig. 6D, Supporting Information Fig. 8), further supporting the disruption of MET during the reprogramming of JNK deficient samples.

 

In this manuscript, we investigated the expression of key components of JNK/SAPK signaling and found that this pathway is activated as early as day 3 of reprogramming with both partially reprogrammed cells (TRA-1-60+CD44+) and fully reprogrammed cell populations (TRA-1-60+CD44-) showing an increase in the number of pSAPK expressing cells until day 18, regardless of the reprogramming protocol used. In contrary to our first expectations, we found that inhibition of JNK/SAPK signaling pathway either by chemical inhibitors or RNAi mediated downregulation of MKK4, MKK7 or JNK1 resulted in the complete abrogation of hiPSC colony formation and emergence of partially reprogrammed cells which were lost during the maturation stage of reprogramming. Together these data highlight the importance of this signaling pathway in human somatic cell induced reprogramming which to the best of our knowledge has not been reported previously. In contrast to our findings, it has been reported that Jnk1-/- and Jnk2-/- murine fibroblasts exhibit a greater potency for reprogramming due to increased Klf4 activity which is phosphorylated by Jnk1 and Jnk2 through inhibitory phosphorylation at Thr residues 224 and 225 [17]. These differences in the role of JNK signaling during the reprogramming of mouse versus human somatic cells can reflect different modes of actions for this pathway in each species; however this needs to be investigated further. We were also surprised to see the lack of functional redundancy between various components of key signaling molecules involved in JNK signaling as downregulation of MKK4, MKK7 and JNK1 in fibroblasts led in all cases to complete absence of hiPSC colonies. Notwithstanding this, we would like to point out that all single component downregulation by RNAi led to further changes in the expression of additional components of this pathway (e.g., MKK4 shRNA resulted in downregulation of MKK7 and JNK1) and/or parallel pathways such as p38, thus outlining the complexity of regulation of this pathway which has been reported previously and must be taken into account when investigating the function of separate signaling components [32-34]. Furthermore, we observed some differences in the expression of key components of JNK/SAPK signaling between neonatal and adult fibroblasts as well as their response to JNK/SAPK inhibition which indicates differences in the mode of operation of this pathway in these two cell types. Nevertheless, the activation window of JNK/SAPK signaling during the reprogramming process and the outcome of JNK/SAPK downregulation in the reprogramming of both cell types were very similar, suggesting that at least the JNK/SAPK functions related to reprogramming are likely to be conserved in both cell types. Human cord blood and hair follicle epithelial cells have emerged as new sources of somatic cells for reprogramming because of their accessibility. Recent reports suggest that JNK/SAPK signaling is required in cord blood cells to prevent the onset of senescence [35], while regulating apoptosis in hair follicle epithelial cells [36]. While our experiments have only been performed in dermal skin neonatal and adult fibroblasts thus preventing to make sound conclusions about the applicability of our findings in other cell types, the well-known role of JNK/SAPK signaling in maintaining cell survival and proliferation may suggest a critical role for this pathway during the reprogramming process; however this has to be further investigated experimentally.

The functions of JNK/SAPK signaling are complex and encompass a wide range of cellular processes which yield different outcomes in specific cell types [37]. Given the increased expression of key components of JNK/SAPK signaling during the initiation and maturation phases of reprogramming, we sought to identify its involvement in several processes shown to be important during this time window namely induction of MET [38], silencing of tumor suppressor and cell cycle inhibitor genes [8], induction of apoptosis [39] and induction of cell proliferation [40, 41]. Consistent with previous reports [42], we found that inhibition of JNK signaling did not have any impact on the apoptosis of fibroblasts undergoing reprogramming (data not shown); hence the link between apoptosis induction and JNK signaling can be excluded. JNK signaling has been shown to be required for the expression of c-Jun and JunD, two essential components of the AP1 transcription factor which is essential for cell proliferation and prevention of senescence often associated with impaired JNK signaling [43]. Despite repeated investigations, we did not observe expression of senescence associated β-galactosidase in fibroblasts with deficient JNK signaling achieved through chemical inhibition or RNAi. Neither did we see an increase in the expression of cell cycle inhibitors including p15, p16, p19 which have been linked to onset of senescence in various cell types [44, 45]. These findings could reflect differences in JNK outcomes in vivo versus in vitro experiments (tissue culture) which have been reported previously, or the time lag that is needed from cell cycle arrest to detectable expression of these markers. Despite lack of senescence marker expression, we observed a significant decrease in cellular proliferation, increased percentage of cells in G1 phase of the cell cycle at the expense of S phase and reduced expression of key cell cycle components involved in G1/S transition (such as CDK6, CDK2, CDK1, CCDN1) and S phase progression and G2/M transition (e.g., CCNB1). It is important to note that such expression changes were specific for each component of the JNK signaling pathway downregulated; however in all cases simultaneous downregulation of at least one CDK and one partnering Cyclin, an event that has been shown to be important for efficient reprogramming [40] was observed. These findings were further corroborated by decreased expression of cellular proliferation markers c-Jun, E2F2 and ATF2 in all three shRNA treated samples consistent with previous reports indicating an important role for MKK4, MKK7 and JNK1 for cell cycle progression [16, 46]. High cellular proliferation rate akin to ESC state is an important early event for cellular reprogramming [40]. This leads us to suggest that suppressed cellular proliferation and cell accumulation at the G1 phase (both known as reprogramming barriers; [47]) at the onset of reprogramming of JNK1, MKK4 and MKK7 deficient neonatal and adult fibroblasts is a key reason for the complete lack of hiPSC observed during reprogramming of these samples.

The efficiency of reprogramming can be promoted by the onset of epithelial expression markers concomitantly with the repression of mesenchymal markers in cells undergoing reprogramming during the 6th until the 12th day of reprogramming, known as initiation phase [48, 49]. This is precisely the window during which the JNK signaling is activated; hence we asked the question of whether MET transition is affected in JNK deficient cells. Our data suggest that while control cells showed well organized TRA-1-60 + colonies characterized by plasma membrane staining of E-cadherin and β-catenin indicating formation of adherent junctions typical of epithelial cells, JNK deficient cells displayed a reduced percentage of cells expressing these markers at both cellular and mRNA levels, which suggests that fewer cells are able to undergo MET transition, thus leading to inefficient reprogramming. Furthermore, the cellular networks that guarantee cell-cell communication while present and well organized in control cells were lacking in JNK/SAPK deficient fibroblasts. It has been suggested that expression of E-cadherin and the presence of intact adherent junctions are essential for maintenance of pluripotency in hESC by ensuring access to critical autocrine signals and by promoting cell-cell exchange of signals through the gap junctions [49, 50]. In this context, it is interesting to note that all colonies that emerged during reprogramming of JNK/SAPK deficient fibroblasts were partially reprogrammed and completely disaggregated and subsequently lost during the maturation stage of reprogramming thus leading us to suggest that deficient JNK/SAPK signaling followed by impaired cell to cell contact is likely to be one of the causative factor that counts for the partially reprogrammed phenotype and for the loss of colonies.

Our inhibition experiments were performed during the initiation stage of reprogramming. In all cases despite the time of JNK/SAPK downregulation we obtained no hiPSC colonies. However, we did not perform JNK/SAPK downregulation studies at the stabilization stage where hiPSC colonies are present and continue to grow and develop. There were two main reasons behind this decision: (1) JNK/SAPK activation occurs during the initiation and maturation stage and shows a drop during the stabilization stage and (2) our data presented in this manuscript together with published reports indicate loss of pluripotency in hESCs upon JNK downregulation [19], which would suggest that downregulation of JNK/SAPK signaling after the emergence of hiPSC colonies would result in their differentiation and thus provide a further push toward loss of true bona fide hiPSC colonies.

 

Together our data indicate an increase in JNK/SAPK activity during the initiation and maturation phases of reprogramming regardless of the reprogramming protocol and an indispensable role for the generation of hiPSC colonies. Furthermore, we have shown that inhibition of JNK/SAPK signaling results in reduced cell proliferation, disruption of MET and loss of pluripotent phenotype which either singly or in combination prevent establishment of pluripotent colonies as shown in the summary (Fig. 7).

http://onlinelibrary.wiley.com/store/10.1002/stem.2327/asset/image_t/stem2327-fig-0007-t.gif

 

Figure 7. Schematic summary showing the impacts of MKK4, MKK7 and JNK1 signaling on hiPSC generation. Abbreviations: hiPSC, human induced pluripotent stem cell; JNK, c-Jun N-terminal kinase; MET, mesenchymal to epithelial transition; MKK, MAP kinase kinases; SAPK, stress-activated protein kinase.

 

sjwilliamspa commented on JNK/SAPK Signaling and iPSC

JNK/SAPK Signaling and iPSC Larry H Bernstein, MD, FCAP, Curator LPBI JNK/SAPK Signaling is Essential for …

This seems like a resulting effect rather than an initial event as it would have been better to use a JNK isoform Knockdown or knockout to determine JNK/STAT requirement. However would be interesting to see if inhibitor washout would reverse phenotype then cold control the process better. JNK activation has been linked to certain tumorigenesis including leukemias as well as breast ovarian and some myelodysplastic syndromes.

Read Full Post »